United States

Almirall SA (ALM.MC)

ALM.MC on Madrid SE C.A.T.S.

24 Mar 2017
Change (% chg)

€-0.11 (-0.74%)
Prev Close
Day's High
Day's Low
Avg. Vol
52-wk High
52-wk Low


Chart for ALM.MC


Almirall SA is a Spain-based company principally engaged in the pharmaceuticals manufacture. The Company focuses on development and marketing of drugs applied in various therapeutic areas, such as nervous system, gastrointestinal, dermatological, respiratory system, antiinfectives, as well as antineoplastic and immunomodulating... (more)


Beta: 0.25
Market Cap(Mil.): €2,570.05
Shares Outstanding(Mil.): 172.95
Dividend: 0.19
Yield (%): 1.28


  ALM.MC Industry Sector
P/E (TTM): 34.05 28.94 29.72
EPS (TTM): 0.44 -- --
ROI: 3.23 13.46 13.00
ROE: 5.06 14.38 14.15

BRIEF-Astrazeneca signs deal with Circassia over Almirall's products

* Astrazeneca enters into a strategic collaboration with Circassia for the development and commercialization of Tudorza and Duaklir in the United States

Mar 17 2017

BRIEF-Almirall appoints new chief scientific officer

* Appoints dermatologist Bhushan Hardas as chief scientific officer and executive vice president research and development, starting in April 2017

Mar 17 2017

BRIEF-Almirall and Symatese enter into collaboration for development of aesthetics products

* Almirall and Symatese enter into a global strategic collaboration for development and commercialization of products in the aesthetics field

Mar 16 2017

BRIEF-Almirall presents new data from Tildrakizumab clinical development program

* Says presented new analyses of phase 1 and pivotal phase 3 clinical trials of Tildrakizumab, an inhibitor IL-23p19 which is currently being evaluated in patients with moderate-to-severe plaque psoriasis, during an annual meeting of American Academy of Dermatology

Mar 07 2017

BRIEF-Almirall to amortize senior bonds due 2021, signs revolving credit facility

* To amortize senior 4.625 percent bonds issued on March 27, 2014 in the amount of 324 million euros ($342.5 million) and maturing in 2021

Feb 27 2017

BRIEF-Almirall EBITDA grows 10.6 pct in FY 2016

* FY EBITDA up 10.6 percent at 227.6 million euros ($240.5 million) versus 205.7 million euros year ago

Feb 27 2017

BRIEF-Almirall reaches agreement with employees for restructuring in Spain

* Says reaches agreement to implement restructuring plan in Spain, reduces to 102 from 121 a number of employees affected

Nov 24 2016

BRIEF-Almirall reports 9-month net profit up 41 percent

* Reports 9-month EBITDA up 6.5 percent at 183.8 million euros ($203.4 million) versus 172.6 million euros year ago

Nov 07 2016

BRIEF-Almirall presents restructuring plan affecting 121 jobs

* Presents restructuring plan in Spain affecting up to 121 jobs

Oct 18 2016

BRIEF-Almirall announces data from pivotal phase-3 clinical trials with inhibitor to treat psoriasis

* Announces results from two pivotal phase-3 clinical trials (reSURFACE 1 and 2) achieving primary endpoint of Tildrakizumab, an investigational IL-23p19 inhibitor, in patients with moderate-to-severe plaque psoriasis Source text for Eikon:

Oct 03 2016

More From Around the Web

Earnings vs. Estimates